Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 basket trial of Leronlimab for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications

Next Previous
Trial Profile

A phase 2 basket trial of Leronlimab for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colon cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Lung cancer; Malignant melanoma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Solid tumours; Testicular cancer; Triple negative breast cancer; Uterine cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Nov 2021 According to a CytoDyn media release, the company has submitted to the U.S. Food and Drug Administration (FDA) an application for Breakthrough Therapy designation (BTD) for leronlimab as a potential treatment for mTNBC. This BTD application is based on the pooled data analysis reported by the company on November 3, 2021.
    • 03 Nov 2021 Pooled data from the Compassionate Use Study (NCT04313075, N =16), the Phase 1b/2 Study ( NCT03838367, N =10), and the Basket Study (N =2) from patients with CCR5+ Metastatic Triple-Negative Breast Cancer who had failed at least two lines of previous therapy are presented in a CytoDyn media release.
    • 01 Jul 2021 According to a CytoDyn media release, triple-negative breast cancer dose escalation portion is completed with the main trial beginning in July.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top